The Faculty of Medicine, Chulalongkorn University, the second oldest medical school in Thailand, was established in 1947 in accordance with the wishes of King Ananda Mahidol to educate a sufficient number of medical doctors to satisfy the public's demands.

During the past decade, Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" #1 sponsor was "Celgene" with 2 trials, followed by "Chulalongkorn University" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "The HIV Netherlands Australia Thailand Research Collaboration" with 2 trials sponsored and "Mahidol University" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" #1 collaborator was "Bamrasnaradura Infectious Diseases Institute" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Bhumibol Adulyadej Hospital" with 1 trials as a collaborator, "Chest Division, Chulalongkorn University" with 1 trials as a collaborator and "Chulalongkorn University" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" are "Cardiovascular Disease" (2 trials), "Anti-VEGF" (1 trials), "Beta-Thalassemia" (1 trials), "Beta-thalassemia" (1 trials) and "Bevacizumab" (1 trials). Many other conditions were trialed in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" in a lesser frequency.

Most popular intervention types in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" are "Drug" (8 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Luspatercept" (2 trials), "bococizumab (PF-04950615)" (2 trials), "AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose" (1 trials) and "AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital" are 9 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Chulalongkorn University Faculty of Medicine - King Chulalongkorn Memorial Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".